These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31301246)

  • 1. Considerations for the Use of Mutation as a Regulatory Endpoint in Risk Assessment.
    Klapacz J; Gollapudi BB
    Environ Mol Mutagen; 2020 Jan; 61(1):84-93. PubMed ID: 31301246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation as a Toxicological Endpoint for Regulatory Decision-Making.
    Heflich RH; Johnson GE; Zeller A; Marchetti F; Douglas GR; Witt KL; Gollapudi BB; White PA
    Environ Mol Mutagen; 2020 Jan; 61(1):34-41. PubMed ID: 31600846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Interpretation of Genetic Toxicity Dose-Response Data for Risk Assessment and Regulatory Decision-Making: Current Status and Emerging Priorities.
    White PA; Long AS; Johnson GE
    Environ Mol Mutagen; 2020 Jan; 61(1):66-83. PubMed ID: 31794061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the adverse outcome pathway framework to genotoxic modes of action.
    Sasaki JC; Allemang A; Bryce SM; Custer L; Dearfield KL; Dietz Y; Elhajouji A; Escobar PA; Fornace AJ; Froetschl R; Galloway S; Hemmann U; Hendriks G; Li HH; Luijten M; Ouedraogo G; Peel L; Pfuhler S; Roberts DJ; Thybaud V; van Benthem J; Yauk CL; Schuler M
    Environ Mol Mutagen; 2020 Jan; 61(1):114-134. PubMed ID: 31603995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a next generation framework for assessment of genomic damage: A case study using the industrial chemical benzene.
    Luijten M; Ball NS; Dearfield KL; Gollapudi BB; Johnson GE; Madia F; Peel L; Pfuhler S; Settivari RS; Ter Burg W; White PA; van Benthem J
    Environ Mol Mutagen; 2020 Jan; 61(1):94-113. PubMed ID: 31709603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In utero Exposure to Genotoxicants Leading to Genetic Mosaicism: An Overlooked Window of Susceptibility in Genetic Toxicology Testing?
    Godschalk RWL; Yauk CL; van Benthem J; Douglas GR; Marchetti F
    Environ Mol Mutagen; 2020 Jan; 61(1):55-65. PubMed ID: 31743493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the importance of low-molecular weight (ethylene oxide- and propylene oxide-induced) DNA adducts and mutations in risk assessment: Insights from 15 years of research and collaborative discussions.
    Pottenger LH; Boysen G; Brown K; Cadet J; Fuchs RP; Johnson GE; Swenberg JA
    Environ Mol Mutagen; 2019 Mar; 60(2):100-121. PubMed ID: 30536466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies in genotoxicology: Acceptance of innovative scientific methods in a regulatory context and from an industrial perspective.
    Steiblen G; Benthem JV; Johnson G
    Mutat Res Genet Toxicol Environ Mutagen; 2020 May; 853():503171. PubMed ID: 32522346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global regulatory requirements for mutagenicity assessment in the registration of industrial chemicals.
    Ji Z; Ball NS; LeBaron MJ
    Environ Mol Mutagen; 2017 Jun; 58(5):345-353. PubMed ID: 28543740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of the in vitro transgene mutation assay in MutaMouse FE1 cells: Evaluation of nine misleading ("False") positive chemicals.
    Maertens RM; Long AS; White PA
    Environ Mol Mutagen; 2017 Oct; 58(8):582-591. PubMed ID: 28843037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment and global regulatory requirements for genetic toxicity evaluations of medical devices.
    Przygoda RT
    Environ Mol Mutagen; 2017 Jun; 58(5):375-379. PubMed ID: 28573657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotoxicity testing: progress and prospects for the next decade.
    Turkez H; Arslan ME; Ozdemir O
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1089-1098. PubMed ID: 28889778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure-response relationships and points of departure (PoDs).
    MacGregor JT; Frötschl R; White PA; Crump KS; Eastmond DA; Fukushima S; Guérard M; Hayashi M; Soeteman-Hernández LG; Kasamatsu T; Levy DD; Morita T; Müller L; Schoeny R; Schuler MJ; Thybaud V; Johnson GE
    Mutat Res Genet Toxicol Environ Mutagen; 2015 May; 783():55-65. PubMed ID: 25953400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk.
    MacGregor JT; Frötschl R; White PA; Crump KS; Eastmond DA; Fukushima S; Guérard M; Hayashi M; Soeteman-Hernández LG; Johnson GE; Kasamatsu T; Levy DD; Morita T; Müller L; Schoeny R; Schuler MJ; Thybaud V
    Mutat Res Genet Toxicol Environ Mutagen; 2015 May; 783():66-78. PubMed ID: 25953401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of genetic toxicity data in GHS mutagenicity classification and labeling of substances.
    Ball NS; Hollnagel HM
    Environ Mol Mutagen; 2017 Jun; 58(5):354-360. PubMed ID: 28485542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations.
    Wills JW; Johnson GE; Doak SH; Soeteman-Hernández LG; Slob W; White PA
    Mutagenesis; 2016 May; 31(3):255-63. PubMed ID: 26687511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic toxicology of ethylenethiourea: a case study concerning the evaluation of a chemical's genotoxic potential.
    Elia MC; Arce G; Hurt SS; O'Neill PJ; Scribner HE
    Mutat Res; 1995 Jan; 341(3):141-9. PubMed ID: 7529355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Ellinger-Ziegelbauer H; Aubrecht J; Kleinjans JC; Ahr HJ
    Toxicol Lett; 2009 Apr; 186(1):36-44. PubMed ID: 18822359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.